Literature DB >> 29158368

Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma.

Kyriakos P Papadopoulos1, Rebecca S Romero2, Gabriela Gonzalez3, James E Dix4, Israel Lowy5, Matthew Fury5.   

Abstract

Autoimmune encephalitis is an uncommon complication of immune checkpoint inhibitor therapy. This article reports a case of fatal anti-Hu-associated autoimmune limbic encephalitis presenting within 8 weeks following anti-PD1 therapy in a patient with myxoid chondrosarcoma and pre-existing anti-Hu antibodies. Although tumor reduction occurred in response to PD-1 inhibitor therapy, the patient had a rapidly progressive decline in neurologic function despite initial stabilization with immunosuppression. Considering the increasing use of immune checkpoint inhibitors for the treatment of various malignancies, an increase in the occurrence of neurologic adverse events is likely, requiring prompt intervention and enhanced pharmacovigilance in malignancies associated with onconeuronal antibodies. © AlphaMed Press 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29158368      PMCID: PMC5759826          DOI: 10.1634/theoncologist.2017-0344

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  13 in total

1.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

Authors:  F Graus; F Keime-Guibert; R Reñe; B Benyahia; T Ribalta; C Ascaso; G Escaramis; J Y Delattre
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

2.  Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.

Authors:  J Dalmau; F Graus; M K Rosenblum; J B Posner
Journal:  Medicine (Baltimore)       Date:  1992-03       Impact factor: 1.889

3.  A myxoid chondrosarcoma associated with an anti-Hu-positive paraneoplastic encephalomyelitis.

Authors:  Michael Hoosien; James Vredenburgh; Julio Lanfranco; Roberto Ochoa; Philip Robinson; Robert Martinez; Carlos Singer; Orlando Silva
Journal:  J Neurooncol       Date:  2010-05-05       Impact factor: 4.130

4.  Hu antigens and anti-Hu antibodies in a patient with myxoid chondrosarcoma.

Authors:  J Verschuuren; A Twijnstra; M De Baets; F Thunnissen; J Dalmau; P van Breda Vriesman
Journal:  Neurology       Date:  1994-08       Impact factor: 9.910

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.

Authors:  S H Gultekin; M R Rosenfeld; R Voltz; J Eichen; J B Posner; J Dalmau
Journal:  Brain       Date:  2000-07       Impact factor: 13.501

7.  Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies.

Authors:  R B Darnell; L M DeAngelis
Journal:  Lancet       Date:  1993-01-02       Impact factor: 79.321

Review 8.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Andreas F Hottinger
Journal:  Curr Opin Neurol       Date:  2016-12       Impact factor: 5.710

9.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

10.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

Authors:  Nicholas McGranahan; Andrew J S Furness; Rachel Rosenthal; Sofie Ramskov; Rikke Lyngaa; Sunil Kumar Saini; Mariam Jamal-Hanjani; Gareth A Wilson; Nicolai J Birkbak; Crispin T Hiley; Thomas B K Watkins; Seema Shafi; Nirupa Murugaesu; Richard Mitter; Ayse U Akarca; Joseph Linares; Teresa Marafioti; Jake Y Henry; Eliezer M Van Allen; Diana Miao; Bastian Schilling; Dirk Schadendorf; Levi A Garraway; Vladimir Makarov; Naiyer A Rizvi; Alexandra Snyder; Matthew D Hellmann; Taha Merghoub; Jedd D Wolchok; Sachet A Shukla; Catherine J Wu; Karl S Peggs; Timothy A Chan; Sine R Hadrup; Sergio A Quezada; Charles Swanton
Journal:  Science       Date:  2016-03-03       Impact factor: 47.728

View more
  16 in total

1.  IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.

Authors:  Lidia Yshii; Béatrice Pignolet; Emilie Mauré; Mandy Pierau; Monika Brunner-Weinzierl; Oliver Hartley; Jan Bauer; Roland Liblau
Journal:  JCI Insight       Date:  2019-04-04

2.  How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.

Authors:  Alberto Vogrig; Sergio Muñiz-Castrillo; Antonio Farina; Jérôme Honnorat; Bastien Joubert
Journal:  J Neurol       Date:  2021-10-27       Impact factor: 4.849

3.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Avi Fellner; Chen Makranz; Michal Lotem; Felix Bokstein; Alisa Taliansky; Shai Rosenberg; Deborah T Blumenthal; Jacob Mandel; Suzana Fichman; Elena Kogan; Israel Steiner; Tali Siegal; Alexander Lossos; Shlomit Yust-Katz
Journal:  J Neurooncol       Date:  2018-01-13       Impact factor: 4.130

4.  Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment.

Authors:  Neus Mongay-Ochoa; Alberto Vogrig; Sergio Muñiz-Castrillo; Jerome Honnorat
Journal:  J Neurol       Date:  2020-05-25       Impact factor: 4.849

5.  Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.

Authors:  Luca Diamanti; Alberto Picca; Paola Bini; Matteo Gastaldi; Enrico Alfonsi; Anna Pichiecchio; Eugenia Rota; Roberta Rudà; Francesco Bruno; Veronica Villani; Edvina Galiè; Alberto Vogrig; Mariarosaria Valente; Marco Zoccarato; Valentina Poretto; Bruno Giometto; Carolina Cimminiello; Michele Del Vecchio; Enrico Marchioni
Journal:  Neurol Sci       Date:  2021-08-23       Impact factor: 3.307

Review 6.  A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.

Authors:  Neeraj Chhabra; Joseph Kennedy
Journal:  J Med Toxicol       Date:  2021-04-07

Review 7.  Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature.

Authors:  Marcos C B Oliveira; Marcelo H de Brito; Mateus M Simabukuro
Journal:  Front Neurol       Date:  2020-12-11       Impact factor: 4.003

Review 8.  [Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors].

Authors:  Hanping Wang; Peng Song; Xiaoyan Si; Xiaoxiao Guo; Yue Li; Jiaxin Zhou; Lian Duan; Li Zhang; Mengzhao Wang; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20

9.  Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study.

Authors:  Guillaume Manson; Alexandre Thibault Jacques Maria; Florence Poizeau; François-Xavier Danlos; Marie Kostine; Solenn Brosseau; Sandrine Aspeslagh; Pauline Du Rusquec; Maxime Roger; Maud Pallix-Guyot; Marc Ruivard; Léa Dousset; Laurianne Grignou; Dimitri Psimaras; Johan Pluvy; Gilles Quéré; Franck Grados; Fanny Duval; Frederic Bourdain; Gwenola Maigne; Julie Perrin; Benoit Godbert; Beatris Irina Taifas; Alexandra Forestier; Anne-Laure Voisin; Patricia Martin-Romano; Capucine Baldini; Aurélien Marabelle; Christophe Massard; Jérôme Honnorat; Olivier Lambotte; Jean-Marie Michot
Journal:  J Immunother Cancer       Date:  2019-12-03       Impact factor: 13.751

Review 10.  Paraneoplastic neurological syndrome: an evolving story.

Authors:  Jiraporn Jitprapaikulsan; Pritikanta Paul; Smathorn Thakolwiboon; Shivam Om Mittal; Sean J Pittock; Divyanshu Dubey
Journal:  Neurooncol Pract       Date:  2021-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.